Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

Sangamo and Pfizer Report Positive Results for Hemophilia A Study

Sangamo Therapeutics and partner Pfizer reported positive results for phase 1/2 Alta study for hemophilia A at the International Society on Thrombosis and Hemostasis Congress in Melbourne, Australia. Sangamo Therapeutics Inc. (SGMO:NASDAQ) shares are up...
Streetwise Reports | July 9, 2019 |

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results

The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. In a press release issued September 24, PhaseBio Pharmaceuticals Inc. (PHAS...
Streetwise Reports | September 26, 2019 |

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

Shares of Moderna Inc. traded up double-digits today as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. This morning clinical-stage biotechnology company Mode...
Streetwise Reports | September 13, 2019 |

Invasive Species

Invasive species: Any kind of living organism—an amphibian (like the cane toad), plant, insect, fish, fungus, bacteria, or even an organism's seeds or eggs—that is not native to an ecosystem and causes harm. They can harm the environment, the economy, or even human he...
Streetwise Reports | August 14, 2019 |

Biopharma's Early Data Show Immunotherapy's Efficacy in Ovarian Cancer

The "encouraging" data for this drug candidate as a monotherapy is the focus of an H.C. Wainwright & Co. report. In a March 26 research note, analyst Joseph Pantginis reported that IMV Inc.'s (IMV:TSX; IMMVD:OTCQX) preliminary monotherapy data confirmed the efficacy o...
Streetwise Reports | April 1, 2019 |

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study

Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. Biopharmaceutical firm Retrophin Inc. (RTRX:NASDAQ) shares are trading much lower today as the co...
Streetwise Reports | August 26, 2019 |

Ardelyx's Shares Soar 65% as Tenapanor Phase 3 Study Hits the Mark

Clinical-stage specialized biopharmaceutical company Ardelyx announced positive results today for its phase 3 AMPLIFY study for tenapanor aimed at improving treatment for cardiorenal diseases. This morning clinical-stage biopharmaceutical developer of medicines for th...
Streetwise Reports | September 4, 2019 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |
1 2 3 4